WG
NTLA icon

Wellington Group’s Intellia Therapeutics NTLA Stock Holding History

Wellington Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
67,688
+21,391
+46% +$299K 0.3% 59
2026
Q1 		$594K Buy
46,297
+15,620
+51% +$199K 0.18% 82
2025
Q4 		$276K Buy
+30,677
New +$422K 0.09% 127

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Wellington Group's NTLA Position: Q2 2026 in Review

Wellington Group increased its Intellia Therapeutics (NTLA) stake by 46% in Q2 2026, buying an estimated $299K and bringing the position to 67,688 shares worth $1.15M. The position accounts for 0.3% of the portfolio, ranked #59.

Wellington Group first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Wellington Group held 67,688 shares of Intellia Therapeutics worth $1.15M as of Q2 2026.
  • Wellington Group bought 21,391 Intellia Therapeutics shares in Q2 2026, an estimated $299K.
  • Intellia Therapeutics made up 0.3% of Wellington Group's portfolio in Q2 2026, its #59 holding.
  • Wellington Group first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Wellington Group's 13F filing for Q2 2026, filed 14 Aug 2026.